Literature DB >> 12618906

Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.

Wojciech Wiszniewski1, Marie-Claude Fondaneche, Pascale Louise-Plence, Ada Prochnicka-Chalufour, Françoise Selz, Cappucine Picard, Françoise Le Deist, Jean-François Eliaou, Alain Fischer, Barbara Lisowska-Grospierre.   

Abstract

MHC class II deficiency is a combined immunodeficiency caused by defects in the four regulatory factors, CIITA, RFXANK, RFX5 and RFXAP, that control MHC II expression at the transcriptional level. The RFXANK gene encodes one subunit of the heterotrimeric RFX complex that is involved in the assembly of several transcription factors on MHC II promoters. Seven different RFXANK mutations have previously been reported in 26 unrelated patients. The most frequent mutation, a 26-bp deletion (752delG-25), has been identified in 21 patients. The other mutations are all nonsense or splice-site mutations, leading to proteins lacking all or part of the RFXANK ankyrin repeat region. We report two novel missense mutations, D121V and R212X, resulting in loss of function of the gene. We investigated the in vivo effects of these mutations and of three other point mutations on the expression of the RFXANK RNA and protein. The number of RFXANK transcripts was severely reduced in all patients except one. The RFXANK protein was barely detected in two cases. In addition, guided by a structural model of RFXANK, we investigated experimental mutants of the C-terminal tyrosine 224. Substitution Y224A, but not Y224F, led to the loss of function of RFXANK. Two null mutants, D121V and Y224A, were tested in protein interaction and DNA binding assays. The D121V mutant was unable to form the RFX complex, indicating that D121 is required for RFXAP binding. The Y224A mutant formed an RFX complex that bound normally to the MHC II promoter, but did not lead to MHC class II expression, whereas Y224F RFXANK retained the wild-type function. This indicates that an aromatic ring, but not the phenyl chain of tyrosine, is necessary at position 224 for normal RFXANK function. Studies on the Y224A mutant suggest that, in addition to the RFX subunits and CIITA, another protein is essential for MHC class II expression. This protein appears to interact with the fourth ankyrin repeat of RFXANK.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12618906     DOI: 10.1007/s00251-002-0521-1

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  21 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B.

Authors:  W Wiszniewski; M C Fondaneche; N Lambert; K Masternak; C Picard; L Notarangelo; K Schwartz; J Bal; W Reith; C Alcaide; G de Saint Basile; A Fischer; B Lisowska-Grospierre
Journal:  Immunogenetics       Date:  2000-04       Impact factor: 2.846

3.  Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP.

Authors:  M Peretti; J Villard; E Barras; M Zufferey; W Reith
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

4.  Associations and interactions between bare lymphocyte syndrome factors.

Authors:  A M DeSandro; U M Nagarajan; J M Boss
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

5.  Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex.

Authors:  N Nekrep; N Jabrane-Ferrat; B M Peterlin
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

6.  A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.

Authors:  K Masternak; E Barras; M Zufferey; B Conrad; G Corthals; R Aebersold; J C Sanchez; D F Hochstrasser; B Mach; W Reith
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

7.  Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes.

Authors:  P Louis-Plence; C S Moreno; J M Boss
Journal:  J Immunol       Date:  1997-10-15       Impact factor: 5.422

8.  RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency.

Authors:  B Durand; P Sperisen; P Emery; E Barras; M Zufferey; B Mach; W Reith
Journal:  EMBO J       Date:  1997-03-03       Impact factor: 11.598

9.  Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d.

Authors:  D H Brotherton; V Dhanaraj; S Wick; L Brizuela; P J Domaille; E Volyanik; X Xu; E Parisini; B O Smith; S J Archer; M Serrano; S L Brenner; T L Blundell; E D Laue
Journal:  Nature       Date:  1998-09-17       Impact factor: 49.962

10.  A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome).

Authors:  V Steimle; B Durand; E Barras; M Zufferey; M R Hadam; B Mach; W Reith
Journal:  Genes Dev       Date:  1995-05-01       Impact factor: 11.361

View more
  12 in total

1.  Mechismo: predicting the mechanistic impact of mutations and modifications on molecular interactions.

Authors:  Matthew J Betts; Qianhao Lu; YingYing Jiang; Armin Drusko; Oliver Wichmann; Mathias Utz; Ilse A Valtierra-Gutiérrez; Matthias Schlesner; Natalie Jaeger; David T Jones; Stefan Pfister; Peter Lichter; Roland Eils; Reiner Siebert; Peer Bork; Gordana Apic; Anne-Claude Gavin; Robert B Russell
Journal:  Nucleic Acids Res       Date:  2014-11-11       Impact factor: 16.971

Review 2.  The ankyrin repeat as molecular architecture for protein recognition.

Authors:  Leila K Mosavi; Tobin J Cammett; Daniel C Desrosiers; Zheng-Yu Peng
Journal:  Protein Sci       Date:  2004-06       Impact factor: 6.725

3.  New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study.

Authors:  Michal Krawczyk; Krzysztof Masternak; Madeleine Zufferey; Emmanuèle Barras; Walter Reith
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

4.  Evolutionary conservation and characterization of the bare lymphocyte syndrome transcription factor RFX-B and its paralogue ANKRA2.

Authors:  Alyssa Bushey Long; Jeremy M Boss
Journal:  Immunogenetics       Date:  2005-01-18       Impact factor: 2.846

5.  The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population.

Authors:  Hamid Naamane; Ouafaa El Maataoui; Fatima Ailal; Abdelhamid Barakat; Siham Bennani; Jilali Najib; Mohammed Hassar; Rachid Saile; Ahmed Aziz Bousfiha
Journal:  Eur J Pediatr       Date:  2010-04-23       Impact factor: 3.183

6.  Formation of the RFX gene regulatory complex induces folding of the interaction domain of RFXAP.

Authors:  LaTese Briggs; Kholiswa Laird; Jeremy M Boss; Colin W Garvie
Journal:  Proteins       Date:  2009-08-15

7.  Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.

Authors:  Thomas Prod'homme; Benjamin Dekel; Giovanna Barbieri; Barbara Lisowska-Grospierre; Rina Katz; Dominique Charron; Catherine Alcaide-Loridan; Shimon Pollack
Journal:  Immunogenetics       Date:  2003-10-22       Impact factor: 2.846

8.  TREC and KREC profiling as a representative of thymus and bone marrow output in patients with various inborn errors of immunity.

Authors:  M Dasouki; A Jabr; G AlDakheel; F Elbadaoui; A M Alazami; B Al-Saud; R Arnaout; H Aldhekri; I Alotaibi; H Al-Mousa; A Hawwari
Journal:  Clin Exp Immunol       Date:  2020-07-21       Impact factor: 4.330

9.  Major Histocompatibility Complex Class II Deficiency due to a Novel Mutation in RFXANK in a Child of Mexican Descent.

Authors:  Katherine Clarridge; David Leitenberg; Brett Loechelt; Capuchine Picard; Michael Keller
Journal:  J Clin Immunol       Date:  2015-12-03       Impact factor: 8.317

10.  Clinical, immunological and genetic features in eleven Algerian patients with major histocompatibility complex class II expression deficiency.

Authors:  Réda Djidjik; Nesrine Messaoudani; Azzedine Tahiat; Yanis Meddour; Samia Chaib; Aziz Atek; Mohammed Elmokhtar Khiari; Nafissa Keltoum Benhalla; Leila Smati; Abdelatif Bensenouci; Mourad Baghriche; Mohammed Ghaffor
Journal:  Allergy Asthma Clin Immunol       Date:  2012-08-03       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.